Answers are grounded in this paper and cite their sources.
Monthly injections of long-acting cabotegravir and rilpivirine were noninferior to standard oral therapy for maintaining HIV-1 suppression. Injection-related adverse events were common but only infrequently led to medication withdrawal. (Funded by ViiV Healthcare and Janssen; ATLAS ClinicalTrials.gov number, NCT02951052.).
No takes yet. Share an insight, caveat, or question.
Swindells et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: